Chiron Behring Formation Complete
Chiron Corporation and Behringwerke, a subsidiary of German chemical and pharmaceutical group Hoechst, have announced the completion of the formation of the joint venture Chiron Behring, through the purchase by Chiron of a 49% stake in the human vaccine business of Behringwerke (Marketletter February 26).
The joint venture, which will research, develop, manufacture and market adult and pediatric vaccines, will be based in Marburg, Germany, and employ around 450 people.
Since the two companies first announced their agreement in February, they have been developing a business strategy and management structure designed to take full advantage of the resources of the two companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze